BioNJ is pleased to share that the Senate confirmed Dr. Stephen Hahn as the next Food and Drug (FDA) Commissioner yesterday in a 72-18 vote.
Dr. Hahn is leaving his post as Chief Medical Executive at Houston's MD Anderson Medical Center. He is taking over from Dr. Ned Sharpless, who has served as acting commissioner after Dr. Scott Gottlieb resigned earlier this year. Dr. Sharpless will return to his job leading the National Cancer Institute.
"Congratulations to Dr. Hahn," said BioNJ President and CEO, Debbie Hart. "America's biopharmaceutical researchers are tireless in their pursuit of new treatments and cures. BioNJ and our New Jersey life sciences industry look forward to working with Dr. Hahn and the entire FDA Team to ensure that Patients continue to have access to innovative therapies in a timely and safe fashion to live longer, healthier and more productive lives "
Because Patients Can't Wait®,
Debbie Hart
President and CEO
Thank You to Our Public Policy Sponsors
If you would like information on how your organization can support our public policy efforts or how to develop an employee advocacy program, please contact John Slotman, BioNJ Vice President, Government Affairs, atJSlotman@BioNJ.org.
